Sedana Medical Q2: Continues to build a base for wider roll-out - Redeye

Redeye lowers its full-year sales estimates for 2022E from SEK 180m to SEK 149m and our 2023-2024E sales by 4-8%, following the report. Once the market normalizes (the company hopes for early 2023), we believe Sedaconda will be more widely implemented in ICUs and its long-term potential will be better recognised by investors. We reiterate our fair value range, consisting of a SEK 101 Base Case.

Länk till analysen i sin helhet: https://www.redeye.se/research/850114/sedana-medical-q2-continues-to-build-a-base-for-wider-roll-out?utm_source=finwire&utm_medium=RSS